Skip to main content
SpringerLink
Log in

Pathophysiology of Obesity-Related Renal Dysfunction Contributes to Diabetic Nephropathy

  • Microvascular Complications—Nephropathy (B Roshan, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Recent studies have demonstrated the role of insulin resistance in renal injury related to obesity, with hyperfiltration leading to glomerulomegaly in a pattern similar to that found in diabetic nephropathy. Similarities in the histologic patterns of damage from obesity and diabetes point to overlapping mechanisms of injury. In this review, we will examine the hormonal mechanisms, signaling pathways and injury patterns in renal injury resulting from obesity and attempt to draw conclusions on the reasons for these similarities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Preble WE. Obesity: Observation on one thousand cases. Boston Med Surg J. 1923;188:617–21.

    Article  Google Scholar 

  2. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med. 1974;81:440–7.

    PubMed  CAS  Google Scholar 

  3. Cohen AH. Massive obesity and the kidney. A morphologic and statistical study. Am J Pathol. 1975;81:117–30.

    PubMed  CAS  Google Scholar 

  4. Verani RR. Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis. 1992;20:629–34.

    PubMed  CAS  Google Scholar 

  5. Kambham N, Markowitz GS, Valeri AM, et al. VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.

    Article  PubMed  CAS  Google Scholar 

  6. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.

    Article  PubMed  CAS  Google Scholar 

  7. Morales E, Valero MA, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319–27.

    Article  PubMed  Google Scholar 

  8. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA. 2004;291:2013–6.

    Article  PubMed  CAS  Google Scholar 

  9. Chaudhary BA, Sklar AH, Chaudhary TK, et al. Sleep apnea, proteinuria, and nephrotic syndrome. Sleep. 1988;11:69–74.

    PubMed  CAS  Google Scholar 

  10. Sklar AH, Chaudhary BA. Reversible proteinuria in obstructive sleep apnea syndrome. Arch Intern Med. 1988;148:87–9.

    Article  PubMed  CAS  Google Scholar 

  11. Sklar AH, Chaudhary BA, Harp R. Nocturnal urinary protein excretion rates in patients with sleep apnea. Nephron. 1989;51:35–8.

    Article  PubMed  CAS  Google Scholar 

  12. Tsioufis C, Thomopoulos C, Dimitriadis K, et al. Association of obstructive sleep apnea with urinary albumin excretion in essential hypertension: a cross-sectional study. Am J Kidney Dis. 2008;52:285–93.

    Article  PubMed  Google Scholar 

  13. Casserly LF, Chow N, Ali S, et al. Proteinuria in obstructive sleep apnea. Kidney Int. 2001;60:1484–9.

    Article  PubMed  CAS  Google Scholar 

  14. • Chou YT, Lee PH, Yang CT, et al. Obstructive sleep apnea: a stand-alone risk factor for chronic kidney disease. Nephrol Dial Transplant. 2011;26:2244–50. This article discusses the relationship of sleep apnea, insulin resistance and proteinuria.

    Article  PubMed  Google Scholar 

  15. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens. 1997;10:49S–55S.

    Article  PubMed  CAS  Google Scholar 

  16. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Ren Physiol. 2000;278:F817–22.

    CAS  Google Scholar 

  17. Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol: JASN. 2003;14:1480–6.

    Article  PubMed  Google Scholar 

  18. Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant. 2008;23:3946–52.

    Article  PubMed  CAS  Google Scholar 

  19. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol: JASN. 2010;21:406–12.

    Article  PubMed  CAS  Google Scholar 

  20. Hennige AM, Staiger H, Wicke C, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3:e1765.

    Article  PubMed  Google Scholar 

  21. Ix JH, Shlipak MG, Brandenburg VM, et al. Association between human fetuin-A and the metabolic syndrome: Data from the Heart and Soul Study. Circulation. 2006;113:1760–7.

    Article  PubMed  CAS  Google Scholar 

  22. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol. 2007;165:164–74.

    Article  PubMed  Google Scholar 

  23. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645–56.

    PubMed  CAS  Google Scholar 

  24. Baumann M, von Eynatten M, Dan L, et al. Altered molecular weight forms of adiponectin in hypertension. J Clin Hypertens. 2009;11:11–6.

    Article  CAS  Google Scholar 

  25. Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol. 2006;98:1603–8.

    Article  PubMed  CAS  Google Scholar 

  26. Pineiro R, Iglesias MJ, Gallego R, et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett. 2005;579:5163–9.

    Article  PubMed  CAS  Google Scholar 

  27. Saginova EA, Galliamov MG, Severova MM, et al. The role of leptin, adiponectin and insulin-resistance markers in development of early stages of chronic kidney disease and atherosclerosis of carotid arteries in obese patients. Ter Arkh. 2011;83:47–53.

    PubMed  CAS  Google Scholar 

  28. Ellington AA, Malik AR, Klee GG, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension. 2007;50:708–14.

    Article  PubMed  CAS  Google Scholar 

  29. Coward R, Walsh GI, Koziell A, et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes. 2007;56:1127–35.

    Article  PubMed  CAS  Google Scholar 

  30. Jones N, Blasutig IM, Eremina V, et al. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature. 2006;440:818–23.

    Article  PubMed  CAS  Google Scholar 

  31. • Fornoni A, Jeon J, Varona Santos J, et al. Nephrin is expressed on the surface of insulin vesicles and facilitates glucose-stimulated insulin releases. Diabetes. 2010;59:190–9. This article discusses the role of nephrin, an important glomerular protein, in secretion of insulin vessicles in the pancreas.

    Article  PubMed  CAS  Google Scholar 

  32. Hussain S, Romio L, Saleem M, et al. Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol: JASN. 2009;20:1733–43.

    Article  PubMed  CAS  Google Scholar 

  33. Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol: JASN. 2006;17:3438–46.

    Article  PubMed  CAS  Google Scholar 

  34. Sharma R, Sharma M, Reddy S, et al. Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes. Front Biosci. 2006;11:968–76.

    Article  PubMed  CAS  Google Scholar 

  35. Callera GE, Touyz RM, Tostes RC, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45:773–9.

    Article  PubMed  CAS  Google Scholar 

  36. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211–6.

    Article  PubMed  CAS  Google Scholar 

  37. Goodfriend TL, Ball DL, Egan BM, et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358–63.

    Article  PubMed  CAS  Google Scholar 

  38. Fliser D, Schaefer F, Schmid D, et al. Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension. 1997;30:1156–61.

    Article  PubMed  CAS  Google Scholar 

  39. Blanco S, Bonet J, Lopez D, et al. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl. 2005;93:S10–4.

    Article  PubMed  CAS  Google Scholar 

  40. Saitoh Y, Hongwei W, Ueno H, et al. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Metab. 2009;35:392–7.

    Article  PubMed  CAS  Google Scholar 

  41. • Habibi J, Hayden MR, Sowers JR, et al. Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology. 2011;152:659–68. This article describes a possible nonhemodynamic mechanism by which a non-specific beta blocker may inhibit proteinuria.

    Article  PubMed  CAS  Google Scholar 

  42. Ahima RS. Linking adiponectin to proteinuria. J Clin Invest. 2008;118(5):1619–22.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Diane Young for her help in preparing this article.

Disclosure

Conflicts of interest: G. Bayliss: none; L.A. Weinrauch: none; J.A. D’Elia: has received grant support from the Pat Covelli Foundation, Amgen Corp., and Bayer Laboratories as investigator-initiated research.

Author information

Authors and Affiliations

  1. Division of Kidney Diseases and Hypertension, Rhode Island and Miriam Hospitals, Providence, RI, USA

    George Bayliss

  2. Alpert Medical School, Brown University, Providence, RI, USA

    George Bayliss

  3. Harvard Medical School, Boston, MA, USA

    Larry A. Weinrauch & John A. D’Elia

  4. Renal Unit, Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Boston, MA, USA

    John A. D’Elia

Authors
  1. George Bayliss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry A. Weinrauch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John A. D’Elia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Bayliss.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bayliss, G., Weinrauch, L.A. & D’Elia, J.A. Pathophysiology of Obesity-Related Renal Dysfunction Contributes to Diabetic Nephropathy. Curr Diab Rep 12, 440–446 (2012). https://doi.org/10.1007/s11892-012-0288-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-012-0288-1

Keywords

Search

Navigation